Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia: Secondary Analysis of a Randomized Clinical Trial

Chieh-Hsin Lin, Ping-Kun Chen, Shi-Heng Wang, Hsien-Yuan Lane, Chieh-Hsin Lin, Ping-Kun Chen, Shi-Heng Wang, Hsien-Yuan Lane

Abstract

Importance: Female gender is a major risk factor for dementia; however, gender has not yet been adequately addressed by clinical trials. A recent study demonstrated that sodium benzoate, a D-amino acid oxidase inhibitor, improved cognitive function in early-phase Alzheimer disease.

Objective: To examine the potential gender difference in the effects of benzoate treatment on the behavioral and psychological symptoms of dementia (BPSD).

Design, setting, and participants: This post hoc secondary analysis used data from a randomized, double-masked, placebo-controlled trial conducted in 3 major medical centers in Taiwan and enrolled 97 patients with BPSD. Data were analyzed between February 2014 and November 2017.

Interventions: Six weeks of treatment of 250 to 1500 mg/d of sodium benzoate or placebo.

Main outcomes and measures: The primary outcome measures were Alzheimer disease assessment scale-cognitive subscale (ADAS-cog) and Behavioral Pathology in Alzheimer Disease Rating Scale (BEHAVE-AD) scores.

Results: Among 97 total participants (62 [64%] women; mean [SD] age, 75.4 [7.7] years), 49 patients (30 women and 19 men) were randomized to sodium benzoate, and 48 (32 women and 16 men) were randomized to placebo. Among 62 women, 6-week benzoate treatment significantly surpassed placebo in the effects on ADAS-cog performance (mean [SD] difference in score between baseline and end point, -3.1 [6.4] points vs 0 [4.5] points; Cohen d = 0.56; P = .04) but not BEHAVE-AD performance. In contrast, among 35 men, the 2 treatment groups did not differ significantly in both ADAS-cog and BEHAVE-AD scores. Compared with placebo, benzoate treatment also increased estradiol to follicle-stimulating hormone ratios among women (mean [SD] difference between baseline and end point, 0 [0.2] vs -0.1 [0.3]; P = .03).

Conclusions and relevance: These findings suggest that benzoate treatment may improve cognitive function in women with later-phase dementia. In the future, longer dose-finding trials are warranted to further clarify the efficacy of benzoate for later-phase dementia and investigate the role of sex hormones and other factors in the pathogenesis of dementia.

Trial registration: ClinicalTrials.gov Identifier: NCT02103673.

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

References

    1. Prince M, Ali GC, Guerchet M, Prina AM, Albanese E, Wu YT. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res Ther. 2016;8(1):23. doi:10.1186/s13195-016-0188-8
    1. Nebel RA, Aggarwal NT, Barnes LL, et al. . Understanding the impact of sex and gender in Alzheimer’s disease: a call to action. Alzheimers Dement. 2018;14(9):1171-1183. doi:10.1016/j.jalz.2018.04.008
    1. Trevisan K, Cristina-Pereira R, Silva-Amaral D, Aversi-Ferreira TA. Theories of aging and the prevalence of Alzheimer’s disease. Biomed Res Int. 2019;2019:9171424. doi:10.1155/2019/9171424
    1. Francis PT. Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine. Curr Mol Pharmacol. 2009;2(1):77-82. doi:10.2174/1874467210902010077
    1. Lin CH, Lane HY. The role of N-Methyl-D-aspartate receptor neurotransmission and precision medicine in behavioral and psychological symptoms of dementia. Front Pharmacol. 2019;10:540. doi:10.3389/fphar.2019.00540
    1. Lin CH, Huang YJ, Lin CJ, Lane HY, Tsai GE. NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer’s disease. Curr Pharm Des. 2014;20(32):5169-5179. doi:10.2174/1381612819666140110115603
    1. Huang YJ, Lin CH, Lane HY, Tsai GE. NMDA neurotransmission dysfunction in behavioral and psychological symptoms of Alzheimer’s disease. Curr Neuropharmacol. 2012;10(3):272-285. doi:10.2174/157015912803217288
    1. Steinberg M, Shao H, Zandi P, et al. ; Cache County Investigators . Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23(2):170-177. doi:10.1002/gps.1858
    1. Paulsen JS, Salmon DP, Thal LJ, et al. . Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000;54(10):1965-1971. doi:10.1212/WNL.54.10.1965
    1. Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. JAMA. 1982;248(3):333-335. doi:10.1001/jama.1982.03330030039022
    1. Marcoli M, Bonfanti A, Roccatagliata P, et al. . Glutamate efflux from human cerebrocortical slices during ischemia: vesicular-like mode of glutamate release and sensitivity to A(2A) adenosine receptor blockade. Neuropharmacology. 2004;47(6):884-891. doi:10.1016/j.neuropharm.2004.06.022
    1. Biegon A, Fry PA, Paden CM, Alexandrovich A, Tsenter J, Shohami E. Dynamic changes in N-methyl-D-aspartate receptors after closed head injury in mice: implications for treatment of neurological and cognitive deficits. Proc Natl Acad Sci U S A. 2004;101(14):5117-5122. doi:10.1073/pnas.0305741101
    1. Gusev EI, Skvortsova VI, Dambinova SA, et al. . Neuroprotective effects of glycine for therapy of acute ischaemic stroke. Cerebrovasc Dis. 2000;10(1):49-60. doi:10.1159/000016025
    1. Hsu WY, Lane HY, Lin CH. Medications used for cognitive enhancement in patients with schizophrenia, bipolar disorder, Alzheimer’s disease, and Parkinson’s disease. Front Psychiatry. 2018;9:91. doi:10.3389/fpsyt.2018.00091
    1. Sasabe J, Miyoshi Y, Suzuki M, et al. . D-amino acid oxidase controls motoneuron degeneration through D-serine. Proc Natl Acad Sci U S A. 2012;109(2):627-632. doi:10.1073/pnas.1114639109
    1. Lin CH, Chen PK, Chang YC, et al. . Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2014;75(9):678-685. doi:10.1016/j.biopsych.2013.08.010
    1. Van den Berghe-Snorek S, Stankovich MT. Thermodynamic control of D-amino acid oxidase by benzoate binding. J Biol Chem. 1985;260(6):3373-3379. doi:10.1016/S0021-9258(19)83631-1
    1. Lin CH, Chen PK, Wang SH, Lane HY. Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): a randomized, double-blind, placebo-controlled, 6-week trial. J Psychopharmacol. 2019;33(8):1030-1033. doi:10.1177/0269881119849815
    1. Hönack D, Löscher W. Sex differences in NMDA receptor mediated responses in rats. Brain Res. 1993;620(1):167-170. doi:10.1016/0006-8993(93)90287-W
    1. McRoberts JA, Li J, Ennes HS, Mayer EA. Sex-dependent differences in the activity and modulation of N-methyl-d-aspartic acid receptors in rat dorsal root ganglia neurons. Neuroscience. 2007;148(4):1015-1020. doi:10.1016/j.neuroscience.2007.07.006
    1. Short RA, Bowen RL, O’Brien PC, Graff-Radford NR. Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc. 2001;76(9):906-909. doi:10.1016/S0025-6196(11)62109-5
    1. Kehinde OS, Christianah OI, Oyetunji OA. Ascorbic acid and sodium benzoate synergistically aggravates testicular dysfunction in adult Wistar rats. Int J Physiol Pathophysiol Pharmacol. 2018;10(1):39-46.
    1. Lin CH, Yang HT, Chen PK, Wang SH, Lane HY. Precision medicine of sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD). Neuropsychiatr Dis Treat. 2020;16:509-518. doi:10.2147/NDT.S234371
    1. Sperling RA, Jack CR Jr, Black SE, et al. . Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367-385. doi:10.1016/j.jalz.2011.05.2351
    1. Zahodne LB, Ornstein K, Cosentino S, Devanand DP, Stern Y. Longitudinal relationships between Alzheimer disease progression and psychosis, depressed mood, and agitation/aggression. Am J Geriatr Psychiatry. 2015;23(2):130-140. doi:10.1016/j.jagp.2013.03.014
    1. Lane HY, Chang YC, Su MH, Chiu CC, Huang MC, Chang WH. Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects. J Clin Psychopharmacol. 2002;22(1):4-10. doi:10.1097/00004714-200202000-00002
    1. Devanand DP, Mintzer J, Schultz SK, et al. . Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med. 2012;367(16):1497-1507. doi:10.1056/NEJMoa1114058
    1. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596-608. doi:10.1001/jama.293.5.596
    1. Matsuura A, Fujita Y, Iyo M, Hashimoto K. Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine. Acta Neuropsychiatr. 2015;27(3):159-167. doi:10.1017/neu.2015.1
    1. Lane HY, Lin CH, Green MF, et al. . Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry. 2013;70(12):1267-1275. doi:10.1001/jamapsychiatry.2013.2159
    1. Lin CH, Lin CH, Chang YC, et al. . Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2018;84(6):422-432. doi:10.1016/j.biopsych.2017.12.006
    1. McCarthny CR, Du X, Wu YC, Hill RA. Investigating the interactive effects of sex steroid hormones and brain-derived neurotrophic factor during adolescence on hippocampal NMDA receptor expression. Int J Endocrinol. 2018;2018:7231915. doi:10.1155/2018/7231915
    1. Bellanti F, Matteo M, Rollo T, et al. . Sex hormones modulate circulating antioxidant enzymes: impact of estrogen therapy. Redox Biol. 2013;1:340-346. doi:10.1016/j.redox.2013.05.003
    1. Labhart A. Clinical Endocrinology: Theory and Practice. Springer Science & Business Media; 2015.
    1. Lemini C, Silva G, Timossi C, et al. . Estrogenic effects of p-hydroxybenzoic acid in CD1 mice. Environ Res. 1997;75(2):130-134. doi:10.1006/enrs.1997.3782
    1. Routledge EJ, Parker J, Odum J, Ashby J, Sumpter JP. Some alkyl hydroxy benzoate preservatives (parabens) are estrogenic. Toxicol Appl Pharmacol. 1998;153(1):12-19. doi:10.1006/taap.1998.8544
    1. Harrison PJ. D-amino acid oxidase inhibition: a new glutamate twist for clozapine augmentation in schizophrenia? Biol Psychiatry. 2018;84(6):396-398. doi:10.1016/j.biopsych.2018.06.001
    1. Steele LS, Glazier RH. Is donepezil effective for treating Alzheimer’s disease? Can Fam Physician. 1999;45:917-919.
    1. Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, et al. . Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case-control study. BMJ. 2019;364:l665. doi:10.1136/bmj.l665
    1. Mallery SR, Zeligs BJ, Ramwell PW, Bellanti JA. Gender-related variations and interaction of human neutrophil cyclooxygenase and oxidative burst metabolites. J Leukoc Biol. 1986;40(2):133-146. doi:10.1002/jlb.40.2.133
    1. Kumar V, Anand IS, Ganguly NK. Action of oxygen free radical scavengers and inhibitors on the chemiluminescence response of monocytes and neutrophils in rheumatic fever. Cardioscience. 1993;4(3):171-175.
    1. Kubota K, Ishizaki T. Dose-dependent pharmacokinetics of benzoic acid following oral administration of sodium benzoate to humans. Eur J Clin Pharmacol. 1991;41(4):363-368. doi:10.1007/BF00314969
    1. Zu K, Pizzurro DM, Lewandowski TA, Goodman JE. Pharmacokinetic data reduce uncertainty in the acceptable daily intake for benzoic acid and its salts. Regul Toxicol Pharmacol. 2017;89:83-94. doi:10.1016/j.yrtph.2017.07.012
    1. Stanojevic D, Čomić L, Stefanovic O, Solujic S ( Antimicrobial effects of sodium benzoate, sodium nitrite and potassium sorbate and their synergistic action in vitro. Bulgarian Journal of Agricultural Science. 2009;15(4):308-312. Accessed March 19, 2021.
    1. Chang CH, Lin CH, Lane HY. D-glutamate and gut microbiota in Alzheimer’s disease. Int J Mol Sci. 2020;21(8):2676. doi:10.3390/ijms21082676
    1. Naveed M, Zhou QG, Xu C, et al. . Gut-brain axis: a matter of concern in neuropsychiatric disorders…! Prog Neuropsychopharmacol Biol Psychiatry. 2021;104:110051. doi:10.1016/j.pnpbp.2020.110051
    1. Lin CY, Liang SY, Chang YC, et al. . Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: a randomised, double-blind, placebo-controlled trial. World J Biol Psychiatry. 2017;18(5):357-368. doi:10.3109/15622975.2015.1117654
    1. Scott JG, Baker A, Lim CCW, et al. . Effect of sodium benzoate vs placebo among individuals with early psychosis: a randomized clinical trial. JAMA Netw Open. 2020;3(11):e2024335. doi:10.1001/jamanetworkopen.2020.24335

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren